IndiTreat (2cureX) is a startup based in Denmark.
IndiTreat (2cureX) is a company headquartered in Denmark.
IndiTreat is a family of CE IVD-marked functional drug sensitivity tests developed and run by 2cureX that use patient-derived organoids to predict metastatic colorectal cancer (mCRC) patients' responses and resistance to chemotherapy regimens.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.